# A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct07923357` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07923357](<https://clinicaltrials.gov/study/NCT07923357>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07923357

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 364 participants.

## Technical summary

Registry record NCT07923357. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-30 (anticipated); primary completion 2027-11-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 364 participants (planned count; ClinicalTrials.gov record NCT07923357, source copy `cardio:ctgov-nct07923357-2026-11-06`, retrieved 2026-11-18)
- Planned start: 2026-10-30 (anticipated) (ClinicalTrials.gov record NCT07923357, source copy `cardio:ctgov-nct07923357-2026-11-06`, retrieved 2026-11-18)
- Primary completion: 2027-11-30 (anticipated) (ClinicalTrials.gov record NCT07923357, source copy `cardio:ctgov-nct07923357-2026-11-06`, retrieved 2026-11-18)
- Completion: 2027-11-30 (anticipated) (ClinicalTrials.gov record NCT07923357, source copy `cardio:ctgov-nct07923357-2026-11-06`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT07923357, source copy `cardio:ctgov-nct07923357-2026-11-06`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07923357-2026-11-06`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Condition: Type 2 Diabetes
- Condition: T2DM
- Intervention (Drug): SAL0150 dose 1
- Intervention (Drug): SAL0150 dose 2
- Intervention (Drug): SAL0150 dose 2
- Intervention (Drug): SAL0150 dose 3
- Intervention (Drug): SAL0150 dose 3
- Intervention (Drug): Placebo
- Intervention (Drug): Semaglutide inject 1.0 mg
- Lead sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. (`cardio:org-shenzhen-salubris-pharmaceuticals-co-ltd`)

## Provenance

Content hash: 7d32616a211c54d8a4e216ddef0a242884a7acd01d96f0b9926c793fe75bec42
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
